Post by
Gann999 on May 13, 2022 8:37am
Legacy
The legacy contracts impacted this quarter but they announced prior to results that they had entered the startup and commission phase so one can gather from that that the majority of the impact from the end of legacy has now been incurred and moving forward we will likely see 50 plus million revenue and margins improved let's start with 17 percent as benchmark but likely better.
Comment by
Takis on May 13, 2022 10:59am
This post is not getting enough love. It's dead on. Margins will improve going forward.
Comment by
Gann999 on May 13, 2022 11:10am
Positive takes fall on deaf ears in these times unfortunately.
Comment by
Ciao on May 13, 2022 11:41am
Ex BGX legacy issues, margins were stated by Stephane as being 17%.
Comment by
Gann999 on May 13, 2022 11:47am
Yes but the point is they will deliver more than 2 of the new Biostream units which by the way are lower margin due to learning curve so so 6 in q2 boosts revenue by 10 million at least on better than 17 percent margins a lot of people are focusing on the negative and ignoring this positive fact.
Comment by
kulewater on May 13, 2022 12:02pm
The issue is that they had stated to be passed all the legacy overruns by Q4 last year. Now its 12 months more. Q4 had positive EPS, back into the red this Q for some reason. The optics arent great. And the CFO isnt inspiring confidence.
Comment by
LongoGlueStick on Oct 15, 2022 5:31pm
Kulewater was another incessant, know it all Xebec pumper. He seems to have disappeared from Stockhouse as well. At least in this post, he seems to be admitting that Xebec is a disaster.